<?xml version='1.0' encoding='utf-8'?>
<document id="25656918"><sentence text="Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction."><entity charOffset="65-74" id="DDI-PubMed.25656918.s1.e0" text="bupropion" /><entity charOffset="118-127" id="DDI-PubMed.25656918.s1.e1" text="monoamine" /><pair ddi="false" e1="DDI-PubMed.25656918.s1.e0" e2="DDI-PubMed.25656918.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25656918.s1.e0" e2="DDI-PubMed.25656918.s1.e1" /></sentence><sentence text="The objective of the study was to evaluate the metabolism dependent inhibition of CYP2B6 catalyzed bupropion hydroxylation in human liver microsomes by monoamine oxidase (MAO) inhibitors and to predict the drug-drug interaction potential of monoamine oxidase inhibitors as perpetrators of drug interaction"><entity charOffset="99-108" id="DDI-PubMed.25656918.s2.e0" text="bupropion" /><entity charOffset="152-161" id="DDI-PubMed.25656918.s2.e1" text="monoamine" /><entity charOffset="241-250" id="DDI-PubMed.25656918.s2.e2" text="monoamine" /><pair ddi="false" e1="DDI-PubMed.25656918.s2.e0" e2="DDI-PubMed.25656918.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25656918.s2.e0" e2="DDI-PubMed.25656918.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s2.e0" e2="DDI-PubMed.25656918.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25656918.s2.e1" e2="DDI-PubMed.25656918.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s2.e1" e2="DDI-PubMed.25656918.s2.e2" /></sentence><sentence text=" Human liver microsomal CYP2B6 activities were investigated using bupropion hydroxylation as probe substrate marker"><entity charOffset="66-75" id="DDI-PubMed.25656918.s3.e0" text="bupropion" /></sentence><sentence text=" The results from single point time dependent inhibition and shift assays suggest that clorgyline, pargyline, phenelzine, and selegiline were metabolism based inhibitors of CYP2B6"><entity charOffset="87-97" id="DDI-PubMed.25656918.s4.e0" text="clorgyline" /><entity charOffset="99-108" id="DDI-PubMed.25656918.s4.e1" text="pargyline" /><entity charOffset="110-120" id="DDI-PubMed.25656918.s4.e2" text="phenelzine" /><entity charOffset="126-136" id="DDI-PubMed.25656918.s4.e3" text="selegiline" /><pair ddi="false" e1="DDI-PubMed.25656918.s4.e0" e2="DDI-PubMed.25656918.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25656918.s4.e0" e2="DDI-PubMed.25656918.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s4.e0" e2="DDI-PubMed.25656918.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25656918.s4.e0" e2="DDI-PubMed.25656918.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25656918.s4.e1" e2="DDI-PubMed.25656918.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s4.e1" e2="DDI-PubMed.25656918.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25656918.s4.e1" e2="DDI-PubMed.25656918.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25656918.s4.e2" e2="DDI-PubMed.25656918.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25656918.s4.e2" e2="DDI-PubMed.25656918.s4.e3" /></sentence><sentence text=" In IC50 shift assays, clorgyline, pargyline, phenelzine and selegiline are metabolism based inhibitors of CYP2B6 with fold shit of 3"><entity charOffset="23-33" id="DDI-PubMed.25656918.s5.e0" text="clorgyline" /><entity charOffset="35-44" id="DDI-PubMed.25656918.s5.e1" text="pargyline" /><entity charOffset="46-56" id="DDI-PubMed.25656918.s5.e2" text="phenelzine" /><entity charOffset="61-71" id="DDI-PubMed.25656918.s5.e3" text="selegiline" /><pair ddi="false" e1="DDI-PubMed.25656918.s5.e0" e2="DDI-PubMed.25656918.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25656918.s5.e0" e2="DDI-PubMed.25656918.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s5.e0" e2="DDI-PubMed.25656918.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25656918.s5.e0" e2="DDI-PubMed.25656918.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25656918.s5.e1" e2="DDI-PubMed.25656918.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s5.e1" e2="DDI-PubMed.25656918.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25656918.s5.e1" e2="DDI-PubMed.25656918.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25656918.s5.e2" e2="DDI-PubMed.25656918.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25656918.s5.e2" e2="DDI-PubMed.25656918.s5.e3" /></sentence><sentence text="0-, 3" /><sentence text="7-, 2" /><sentence text="9-, and 11" /><sentence text="4-fold respectively" /><sentence text=" The inactivation of clorgyline was characterized by KI value of 2"><entity charOffset="21-31" id="DDI-PubMed.25656918.s10.e0" text="clorgyline" /></sentence><sentence text="5 ± 0" /><sentence text="3 and k(inact) value of 0" /><sentence text="045 ± 0" /><sentence text="001 min(-1)" /><sentence text=" Phenelzine inactivated CYP2B6 with KI and k(inact) values of 44"><entity charOffset="1-11" id="DDI-PubMed.25656918.s15.e0" text="Phenelzine" /></sentence><sentence text="9 ± 6" /><sentence text="9 μM and 0" /><sentence text="085 ± 0" /><sentence text="003 min(-1) respectively" /><sentence text=" Inactivation of selegiline was characterized with KI and k(inact) values of 22"><entity charOffset="17-27" id="DDI-PubMed.25656918.s20.e0" text="selegiline" /></sentence><sentence text="0 ± 3" /><sentence text="3 and 0" /><sentence text="074 ± 0" /><sentence text="002 min(-1) respectively" /><sentence text=" The inactivation caused by these inhibitors was not reversed by dialysis indicating irreversible inhibition" /><sentence text=" Based on the mechanistic static model, selegiline showed an increase in the area under the curve (AUC) of efavirenz and bupropion by 1"><entity charOffset="40-50" id="DDI-PubMed.25656918.s26.e0" text="selegiline" /><entity charOffset="107-116" id="DDI-PubMed.25656918.s26.e1" text="efavirenz" /><entity charOffset="121-130" id="DDI-PubMed.25656918.s26.e2" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.25656918.s26.e0" e2="DDI-PubMed.25656918.s26.e0" /><pair ddi="false" e1="DDI-PubMed.25656918.s26.e0" e2="DDI-PubMed.25656918.s26.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s26.e0" e2="DDI-PubMed.25656918.s26.e2" /><pair ddi="false" e1="DDI-PubMed.25656918.s26.e1" e2="DDI-PubMed.25656918.s26.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s26.e1" e2="DDI-PubMed.25656918.s26.e2" /></sentence><sentence text="01-fold" /><sentence text=" Phenelzine predicted to cause an increase in the AUC of efavirenz and bupropion by 9"><entity charOffset="1-11" id="DDI-PubMed.25656918.s28.e0" text="Phenelzine" /><entity charOffset="57-66" id="DDI-PubMed.25656918.s28.e1" text="efavirenz" /><entity charOffset="71-80" id="DDI-PubMed.25656918.s28.e2" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.25656918.s28.e0" e2="DDI-PubMed.25656918.s28.e0" /><pair ddi="false" e1="DDI-PubMed.25656918.s28.e0" e2="DDI-PubMed.25656918.s28.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s28.e0" e2="DDI-PubMed.25656918.s28.e2" /><pair ddi="false" e1="DDI-PubMed.25656918.s28.e1" e2="DDI-PubMed.25656918.s28.e1" /><pair ddi="false" e1="DDI-PubMed.25656918.s28.e1" e2="DDI-PubMed.25656918.s28.e2" /></sentence><sentence text="4- and 2" /><sentence text="4-fold respectively considering unbound hepatic inlet concentrations of phenelzine"><entity charOffset="72-82" id="DDI-PubMed.25656918.s30.e0" text="phenelzine" /></sentence><sentence text=" In conclusion, the results from this study demonstrated that MAO inhibitors can inactivate human liver microsomal CYP2B6" /><sentence text=" The likelihood of drug interaction when selegiline co-administered with CYP2B6 substrates is remote"><entity charOffset="41-51" id="DDI-PubMed.25656918.s32.e0" text="selegiline" /></sentence><sentence text=" Caution is required while co-administering phenelzine with substrates that are exclusively metabolized by CYP2B6 enzyme and substrates that have narrow therapeutic index"><entity charOffset="44-54" id="DDI-PubMed.25656918.s33.e0" text="phenelzine" /></sentence><sentence text="" /></document>